Esbriet

Many IPF Patients in Europe Not Given Approved Treatments, Survey Finds

Despite the availability of approved antifibrotic treatments for idiopathic pulmonary fibrosis (IPF), many patients in Europe do not receive them, partly due to a lack of awareness by physicians or a preference for a “wait and watch” approach in people with stable or milder disease, a survey reveals. Better education…

6 Tips for Protecting Your Lungs

We only get one set of lungs so it’s imperative that we look after them. This is even more important with diseases that directly affect the lungs as it could help slow down the progression of the disease and ease the symptoms.  To help you take the best possible care of your lungs,…

FibroGen Shares Positive Results of Phase 2 Trial of Investigational Therapy Pamrevlumab

A Phase 2 trial testing the investigational therapy pamrevlumab (FG-3019) in patients with idiopathic pulmonary fibrosis (IPF) has shown positive and encouraging results, FibroGen, the drug’s developer, announced. In addition, combining pamrevlumab with the FDA-approved IPF therapies Esbriet (pirfenidone) and Ofev (nintedanib) was found to be safe. These results will be…

Measures of IPF Therapy Effectiveness Should Include Patients’ Views of Success, Researchers Argue

Clinical trials of idiopathic pulmonary fibrosis (IPF) therapies should include measures that reflect patients’ views of the success of treatments, Columbia University Medical Center researchers contend. In particular, the trials should add reduction in respiratory-related hospitalizations to their measurement tool kit, the team said. Patients’ views of treatment success could influence…